How we work

AI, proprietary technology and a clear plan for your product.

We scope each engagement around your product, stage and target markets. Our working method sets milestones and responsibilities; Market-Ready by Design connects the product, evidence and adoption work. Choose staged consulting, algorithm licensing or co-development with profit share.

InsightAssess the product, technology and market against our database and experience.
StrategySet the use case, claims, evidence plan, market sequence and commercial model.
ConnectIdentify the technology and specialist partners needed, including clinical partners, hospitals and key opinion leaders. Integrate our algorithm where it fits the product.
ExecuteCarry out the agreed product and strategy work against milestones. Clinical partners conduct clinical studies within their assigned scope.
ValidateReview technical results, clinical evidence and market assumptions with the relevant specialists, and revise the plan when findings require it.
Launch & learnPrepare for launch and plan how authorised real-world data can inform monitoring and future development.

The stages overlap and may be revisited as findings emerge. Evidence, quality and target-market requirements are considered throughout; scope and responsibilities are agreed for each engagement.

For medical device R&D teams

Market-Ready by Design

We engage at concept and design input to align intended use, claims, evidence needs and target-market priorities alongside product development. AI-assisted analysis supports defined tasks under specialist review. Where relevant, we assess integration of our proprietary database and clinically proven algorithm. We lead the evidence plan, publication strategy and clinical network coordination; clinical partners conduct clinical studies. Launch preparation develops alongside the product, with support toward medical and clinical status and approval where required.

For medical device companies

Product ClarityShape your device or sensing concept around a defined medical need, with design inputs connecting technology to intended use.AI-assisted analysis supports comparison of product concepts and design-input gaps, reviewed by product and R&D specialists.
Target-Market FitAlign your product and go-to-market direction with the target market’s care pathways, including expansion between China and Western markets in either direction.AI-assisted analysis supports comparison of target-market needs and care pathways, reviewed by clinical and market specialists.
Expert ConnectionsConnect with relevant hospitals and key opinion leaders to bring practical insight into development and build relationships ahead of launch.AI-assisted analysis supports mapping of hospital expertise and published research interests, reviewed by clinical and partnership specialists.
Evidence RoadmapExperts lead evidence and publication planning, clinical partners run studies, and human authors remain accountable for publications.AI-assisted analysis supports literature mapping and evidence-gap assessment, reviewed by clinical research and publication specialists.
Adoption ReadinessPrepare launch materials, user education and evidence-based communication to support product introduction and build relevant brand visibility.AI-assisted analysis supports assessment of adoption barriers and launch-message gaps, reviewed by clinical and go-to-market specialists.
In-Market GrowthTurn sales feedback and real-world use insights into priorities for product development, customer engagement and further growth.AI-assisted analysis supports assessment of sales patterns and real-world feedback, reviewed by commercial and product specialists.

Vie Nova leads strategy, evidence planning and clinical network coordination. Clinical partners conduct clinical studies. Product claims, launch timing and publication plans depend on the evidence and the relevant independent decisions.

AI supports analysis and preparation for defined tasks across R&D, product and sales, under specialist review. Its role is agreed for each engagement. Our proprietary database and clinically proven algorithm are separate assets, applied where relevant. Clinical partners conduct clinical studies; human authors are responsible for publications.

Why Vie Nova

What we bring together.

Our own technology, AI capabilities, medical device experience and one coordinated plan, from concept toward clinical adoption. The comparison below illustrates the risks of disconnected work and how we address them; it is not a claim about every alternative provider.

01
When strategy starts
When work is disconnected Clinical and market questions considered after key design decisionsVie Nova Clinical and market questions considered from concept and design input
02
Who is involved
When work is disconnected Separate workstreams without shared responsibilitiesVie Nova One coordinated plan, with responsibilities agreed for Vie Nova and specialist partners
03
Technology
When work is disconnected Technology choices assessed separately from the product planVie Nova Our database and clinically proven algorithm assessed for fit alongside product planning
04
Evidence
When work is disconnected Evidence and publication plans developed separatelyVie Nova Expert-led evidence planning and publication strategy aligned with development
05
Clinical network
When work is disconnected Clinical input sought late in developmentVie Nova Hospital and key opinion leader engagement planned during development
06
Markets
When work is disconnected Each market planned without considering the othersVie Nova Selected markets considered together, with local requirements and expertise identified
07
AI
When work is disconnected Tools introduced without a defined use case or reviewerVie Nova AI tasks, data permissions and specialist review defined for the engagement
08
Commercial alignment
When work is disconnected Scope and commercial incentives left unclearVie Nova Staged consulting fees, algorithm licensing or co-development with agreed profit share

Vie Nova leads strategy, evidence planning and network coordination. Clinical partners conduct clinical studies. Regulatory decisions rest with each market’s authority; launch, adoption and publication outcomes cannot be guaranteed.

How we will work

A senior lead, agreed milestones

A named senior lead coordinates Vie Nova’s work across the agreed engagement.
Our technology and IP can be licensed, integrated or co-developed where they fit your product.
Ownership, decision rights and IP terms are written down before work starts.
One plan connects R&D, product, clinical, regulatory and commercial dependencies.
Deliverables, assumptions, acceptance criteria and next decisions are explicit.
Work done by Vie Nova and by specialist partners is described transparently.

Engagement models

Three ways to work with us.

Staged consulting

Consulting fees agreed by stage, with a defined scope, deliverables and decision points for each phase.

Algorithm licence

License our clinically proven algorithm for an agreed product, intended use and markets, with integration and validation responsibilities defined in the terms.

Co-development

Develop a product with us under an agreed scope, with profit share, IP ownership and decision rights defined before work begins.

Terms are agreed before work begins: scope, stages and fees; licence field of use and territory; background and new IP; data responsibilities; confidentiality; and, for co-development, the profit-share basis and decision rights. Models can be combined, for example a staged assessment that leads to a licence or co-development.

Every engagement starts with a defined first stage, scoped and priced before work begins.